Table 3. Clinicopathological parameters on the basis of breast invasive ductal carcinoma subtype.
| Characteristics | HR+HER2− (n = 219) | HR+HER2+ (n = 38) | HER2 (n = 35) | TNBC (n = 126) | p-value | |
|---|---|---|---|---|---|---|
| Histologic grade | < 0.001 | |||||
| I | 64 (29.2) | 5 (13.2) | 1 (2.9) | 6 (4.8) | ||
| II | 115 (25.5) | 25 (65.8) | 16 (45.7) | 35 (27.8) | ||
| III | 40 (18.3) | 8 (21.1) | 18 (51.4) | 85 (67.5) | ||
| Lymph node metastasis | 91 (41.7) | 16 (42.1) | 14 (40.0) | 44 (35.2) | 0.675 | |
| Recurrence | 14 (6.4) | 5 (13.2) | 7 (20.0) | 21 (16.7) | 0.008 | |
| Death | 17 (7.8) | 4 (10.5) | 8 (22.9) | 18 (14.3) | 0.035 | |
| Ki67 LI (%) | 9.52 ± 11.44 | 13.08 ± 10.05 | 12.10 ± 2.05 | 24.20 ± 2.16 | HR+HER2− vs. TNBC, < 0.001* | |
| HR+HER2+ vs. TNBC, < 0.001* | ||||||
| HER2 vs. TNBC, < 0.001* | ||||||
Values are presented as number (%) or mean ± standard deviation.
HR+ = hormone receptor positive; HER2− = human epidermal growth factor receptor 2 negative; HER2+ = human epidermal growth factor receptor 2 positive; TNBC = triple-negative breast cancer; LI = labelling index.
*Bonferroni post hoc test.